Etablissement Public De Sante Barthelemy Durand

The medical center is at the forefront of research into Autism Spectrum Disorders (ASD), focusing on innovative treatments that address core symptoms such as social communication and interaction deficits. The center's work in this area is exemplified by its exploration of the effects of pitolisant, a novel therapeutic agent, in children and adolescents with ASD.

• Social Communication and Interaction Deficits
• Innovative Therapeutic Approaches
• Child and Adolescent Psychiatry

Through rigorous clinical trials, the center aims to enhance the understanding of ASD and improve the quality of life for affected individuals by developing targeted therapies that address specific symptoms.

Specializing in the treatment of Major Depressive Disorder (MDD), the medical center is pioneering research into the early efficacy of ketamine as an add-on therapy to venlafaxine for patients experiencing severe depressive episodes. This research is crucial in understanding the rapid antidepressant effects of ketamine and its potential to transform treatment paradigms for MDD.

• Rapid Antidepressant Effects
• Synaptic Density Changes
• Advanced Neuroimaging Techniques

The center's studies utilize cutting-edge PET-MRI technology to assess synaptic changes, providing insights into the neurobiological mechanisms underlying clinical improvements in depression.